Q3 Revenue Jumps 75%, but Medicare Win Overshadowed by Guidance Cut to $34M
QTI is trading near its 52-week low of $2.01 (12% above the low).
Summary
Q3 revenue rose 75% to $7.3 million on 15 scanner sales, and nine-month revenue hit $21.3 million, roughly double last year. The bigger news is CMS reversing its proposed nonpayment decision on November 4, establishing separate Medicare hospital outpatient payment for diagnostic QTscan exams starting January 1, 2027 — that removes the main reimbursement overhang on the U.S. hospital push. But the company cut full-year 2026 revenue guidance to about $34 million from about $39 million, citing armed conflict and the effective closure of the Strait of Hormuz blocking scanner shipments to Saudi Arabia and UAE distributors. Q3 net loss narrowed to $0.3 million, or $0.02 per share, though that includes a $2.4 million noncash earnout fair-value gain; operating loss actually widened to $2.4 million from $1.7 million as opex climbed. Cash fell to $8.4 million from $11.0 million at June 30, with $11.5 million of inventory sitting on the balance sheet — a thin liquidity cushion against a $100 million shelf already on file. The reimbursement win is real and durable, but the guidance cut and cash burn are what traders will price first.
At the time of this announcement, QTI was trading at $2.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $33.1M. The 52-week trading range was $2.01 to $7.60. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: BusinessWire.